FDAnews Announces — FDA Regulation of Regenerative Medicine: Risks and Opportunities in a Shifting Regulatory Environment Webinar, June 9, 2016

Share Article

The regenerative medicine industry is rapidly growing and, with major court decisions, new and significant FDA guidance, and government enforcement actions, the regulatory landscape is more complex than ever. This webinar will identify key trends and policies affecting the regenerative medicine industry in 2016.

FDA Regulation of Regenerative Medicine:
Risks and Opportunities in a Shifting Regulatory Environment
June 9, 2016 — 1:30 p.m. – 3:00 p.m. ET
http://www.fdanews.com/fdaregulationregenerativemedicine            

The regenerative medicine industry is rapidly growing and, with major court decisions, new and significant FDA guidance, and government enforcement actions, the regulatory landscape is more complex than ever.

This webinar will identify key trends and policies affecting the regenerative medicine industry in 2016 including:

  • How FDA is expected to regulate regenerative medicine in 2016 and beyond
  • How FDA will deal with ethical issues associated with stem cell research
  • How FDA’s oversight of regenerative medicine compares to global regulation
  • How likely it is that Congress will pass legislation on regenerative medicine
  • Why regenerative medicine contains so much political baggage
  • How associations are influencing the regenerative medicine debate

Register today to gain a comprehensive understanding of the FDA’s current regulatory policies and enforcement trends affecting the regenerative medicine industry.

Meet the Presenters:
Andrew Ittleman, Esq., Founder and Partner, Fuerst Ittleman David & Joseph, PL
Andrew Ittleman exclusively represents clients in highly regulated industries, such as regenerative medicine and other FDA-regulated issues. Ittleman has been invited to speak at numerous conferences and panels on FDA enforcement issues, FDA regulation of stem cells and FDA regulation of off-label use. He also litigates extensively against the United States government in civil and criminal matters.

Kelly Lightfoot, Esq., Senior Associate, Fuerst Ittleman David & Joseph, PL
Kelly Lightfoot represents a variety of participants in the regenerative medicine industry, both public and private, including biologics manufacturers, clinical trial sponsors, medical device manufacturers, cryogenic banking facilities, medical tourism businesses, and physicians engaged in the development of autologous stem cell therapies.

Who Will Benefit:

  • Regulatory Affairs
  • Quality Control
  • Legal
  • Business Affairs

Webinar Details:
FDA Regulation of Regenerative Medicine:
Risks and Opportunities in a Shifting Regulatory Environment
June 9, 2016 — 1:30 p.m. – 3:00 p.m. ET
http://www.fdanews.com/fdaregulationregenerativemedicine            

Tuition:
$287 per site

Easy Ways to Register:
Online: http://www.fdanews.com/fdaregulationregenerativemedicine        
By phone: 888-838-5578 or 703-538-7600

About FDAnews:
FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews' print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA's complex and ever-changing regulations.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michelle Butler
FDANEWS
+1 (703) 538-7665
Email >
FDAnews
Like >
Visit website